SAN ANTONIO– LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, today announced the appointment of Todd Lehman as Chief Executive Officer, President and member of the Board of Directors.
Todd joined LumaBridge in April 2023 to head the company’s business development organization, and he quickly made a significant impact as a member of the executive team in driving business growth and process improvements. He brings over 20 years of clinical operations and commercial experience across multiple therapeutic areas, with a particular emphasis on oncology and ophthalmology. Prior to joining LumaBridge, Todd held various leadership roles in operations and portfolio management with a focus on the biotech customer at PPD, a Thermo Fisher Scientific company. Todd began his career in clinical research at Rx Development Resources, the CRO division of Sirion Therapeutics. Todd holds an M.S. in biomedical engineering and a B.S. in chemical engineering, from the University of South Florida.
“Since joining LumaBridge last year, Todd’s contributions have been invaluable, and I am confident that he will be an effective leader for our next phase of growth,” said Dr. George Peoples, LumaBridge Founder and Executive Chairman of the Board of Directors. “He brings a wealth of experience that benefits both sponsors and patients, and I look forward to collaborating with Todd as we continue to scale our clinical trial capabilities.”
“It’s been an honor to be a part of the LumaBridge team during such an exciting stage of the company’s growth,” said Todd Lehman. “I am inspired by our customers’ ongoing efforts to bring innovative solutions to oncology patients, and I look forward to continue working with the team to further advance our capabilities and services as customer demands evolve.”
